+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 75Years
All Genders
ID07862010

Evaluation of GI001 CAR-T Therapy by Intravenous Infusion for Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

Led by Hematology department of the 920th hospital · Updated on 2026-10-07

18

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating GI001, an in vivo CD19-targeted CAR-T cell therapy, in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma B-NHL and B-cell Acute Lymphoblastic Leukemia B-ALL. This open-label, multi-cohort study aims to assess the safety, tolerability, and early effectiveness of GI001. Unlike traditional CAR-T therapies that require lab-based cell manufacturing, GI001 is given directly to patients through intravenous infusion to create CAR-T cells inside the body. The study has two main phases a Dose-Escalation Phase and a Dose-Expansion Phase. The Dose-Escalation Phase tests four increasing dose levels to find the safest and most effective dose, using an accelerated and then standard dose-escalation design. The Dose-Expansion Phase enrolls more participants at the recommended doses to further assess safety, clinical response, and how the therapy behaves in the body. GI001 is given as a single intravenous infusion, with recommended premedication before treatment and no lymphodepleting conditioning. Participants undergo screening and baseline tests before treatment, receive the infusion on Day 0, and are hospitalized for at least 14 days for close monitoring. Safety is watched closely for 28 days after infusion, with follow-up visits up to 24 months and a long-term follow-up period lasting 15 years to monitor survival and any delayed effects. Researchers measure adverse events, vital signs, laboratory values, immune cell levels, and clinical response throughout the study.

CONDITIONS

Brief Title

Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia

Research Team

S

Sanbing Wang Principal Investigator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here